Hydrea

Hydrea is the brand name for the oral antimetabolite hydroxycarbamide, an Rx medication marketed in the European Union. It is supplied without a fixed strength or dosage form specification, and is prescribed for several hematologic conditions. The drug belongs to the antineoplastic agent class and works by interfering with DNA synthesis, making it a key therapy in certain blood disorders.

Hydrea is prescribed for a range of hematologic disorders where abnormal cell proliferation is a concern.

- Chronic myelogenous leukemia (CML) - Sickle cell disease to reduce painful crises - Essential thrombocythemia for platelet count control - Polycythemia vera to lower red blood cell mass - Off‑label use in certain myeloproliferative neoplasms

Hydrea may cause a variety of adverse reactions, ranging from mild to severe.

Common: - Nausea and vomiting - Loss of appetite - Fatigue or weakness - Mild hair thinning - Low white blood cell count (leukopenia) - Elevated liver enzymes

Serious: - Severe bone marrow suppression (pancytopenia) - Acute kidney injury - Life‑threatening infections - Severe skin reactions such as Stevens‑Johnson syndrome

Before starting Hydrea, patients should discuss their medical history and current health status with a healthcare professional.

- Monitor complete blood counts regularly to detect bone marrow suppression. - Assess liver and kidney function before and during therapy. - Use effective contraception; pregnancy safety is unknown. - Avoid use in patients with known hypersensitivity to hydroxycarbamide. - Caution in individuals with pre‑existing immunosuppression or active infections. - Discuss any planned surgeries, as wound healing may be impaired.

Hydrea can interact with several medications, altering its efficacy or increasing toxicity.

Avoid: - Concurrent use of other myelosuppressive agents (e.g., chemotherapy, azathioprine) due to heightened risk of severe cytopenias. - Live vaccines, because immunosuppression may reduce vaccine effectiveness and increase infection risk.

Use with caution: - Allopurinol, which may increase hydroxycarbamide plasma levels. - NSAIDs, as they can exacerbate gastrointestinal irritation. - Anticoagulants, because altered platelet counts may affect bleeding risk. - Drugs affecting renal function, such as ACE inhibitors, may require dose adjustments.